Hepatitis C
Clinical Trials:
Title: A Phase 2 Study of VX-950 in Combination With Peginterferon
Alfa-2a Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with
Hepatitis C.
Population: Naïve to treatment, Hepatitis
C
Coordinator: Fatema Nader (phone: 703-208-6637)
Status:
Closed to enrollment
Title: A partially-blinded, randomized, parallel-group study to
evaluate the potential pharmacokinetic and pharmacodynamic interactions between
Valopicitabine and Ribavirin when administered in combination with Pegylated
Interferon Alfa-2a in treatment-Naïve patients with Chronic Hepatitis
C.
Population: Naïve to treatment, Hepatitis C
Coordinator: Fatema
Nader (phone: 703-208-6637) or Phuong Lee (Phone:
703-208-6649)
Status: Closed to enrollment
Title: A phase 2, randomized, open-label study of the safety,
antiviral activity, and pharmacokinetics of HCV-796 administered in combination
with Peginterferon Alfa 2b plus Ribavirin versus Peginterferon Alfa 2b plus
Rebetol in subjects with Hepatitis C Virus Genotype 1
infection.
Population: Naïve/Nonresponder to treatment, Hepatitis
C
Coordinator: Ine-Mari Bornman (Phone:
703-208-6656)
Status: Open to Enrollment
Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the
Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with
Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in
Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic
Hepatitis C Genotype 1.
Population: Naïve to treatment, Hepatitis
C
Coordinator: Ine-Mari Bornman (Phone:
703-208-6656)
Status: Open to Enrollment
Title: A Phase 2 Study of Telaprevir (VX-950) in Combination with
PeginterferonAlfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with
Genotype1 Hepatitis C Who Have Not Achieved Sustained Viral Response with a
Prior Course of Interferon-Based Therapy.
Population: Non-responder to
treatment, Hepatitis C
Coordinator: Fatema Nader (phone:
703-208-6637)
Status: Closed to enrollment
Title: Randomized, multi-center, double-blinded, Phase IV Study evaluating the
efficacy (as measured by sustained virological response) and safety of 360 ug
induction dosing of Pegasys in combination with higher Copegus doses in
treatment of naïve patients with chronic Hepatitis C Genotype 1 virus infection
of high viral titer and baseline body weight greater than or equal to 85
kg.
Population: Naïve to treatment, Hepatitis C
Coordinator: Archita
Chatterjee
Status: Open to enrollment
Translational Research Studies:
Title: Predictors of Aggressive Disease and Responsiveness to
Pegylated Interferon + Ribavirin in the Treatment of Chronic Hepatitis C
(Predictors 1).
Population: Hepatitis C
Coordinator: Rochelle
Collantes (phone: 703-208-6659)
Status: Open
Title: The Impact of Host Factors on Hepatitis C (Predictors
2)
Population: Hepatitis C.
Coordinator: Rochelle Collantes
(phone: 703-208-6659)
Status: Open
Title: Predictors of Aggressive Disease and Responsiveness to
Pegylated Interferon + Ribavirin in the Treatment of Chronic Hepatitis C:
Proteomic Profiling.
Population: Patients who have chronic HCV
infection, naive or non-responder, and currently on treatment with pegylated
interferon + ribavirin
Coordinator: Rochelle Collantes (phone:
703-208-6659)
Status: Open- not enrolling
Title: Transplant-Related Accelerated Progression of Hepatitis C
(TRAP-C)-NIH led study.
Population: Chronic hepatitis C infected
patients requiring orthotopic liver transplantation for end-stage liver disease.
Patients will be enrolled from the Georgetown University Medical Center Liver
Transplant Institute. Chronic hepatitis infected patients requiring renal
transplantation for end-stage kidney disease will be enrolled from the
Transplantation Branch of the National Institute of Diabetes & Digestive
& Kidney Diseases (NIDDK).
Coordinator: Clare Nugent (Inova Fairfax
Center) (703-208-6617)
Status: Open- not enrolling
Title: Comparative Analysis of Adipokines and Cytokines in NAFLD,
HCV, and HBV.
Population: Non-Alcoholic Fatty Liver Disease (NAFLD),
Hepatitis C (HCV), and Hepatitis B (HBV) patients.
Coordinator: Rochelle
Collantes (phone: 703-208-6659)
Status: Open- not
enrolling
Outcomes Research:
Title: Neuropsychiatric Impact of Pegylated Interferon in Hepatitis C
(NIPIC).
Population: Chronic Hepatitis C virus (HCV) infection
patients with HCV genotype 1 with viremia (HCV RNA measured by PCR) about to
receive treatment with a pegylated interferon-based regimen who do not have A) a
history of depression or B) first degree relatives with a history of
depression.
Coordinator: Jillian Kallman
(703-208-6689)
Status: Open- enrolling
Title: The Impact of Anemia on Health-related Quality of Life of
Patients with Hepatitis C.
Population: Hepatitis C infected
patients as well as patients with various chronic liver
diseases.
Coordinator: Jillian Kallman
(703-208-6689)
Status: Open- no longer enrolling.
Title: Survey of Hepatitis B (HBV), Hepatitis C (HCV), and
Non-Alcoholic Fatty Liver Disease (NAFLD) Screening Factors Community Practices
Study: A Pilot.
Population: GI specialists and Primary Care
Physicians (PCPs)
Coordinator: Jillian Kallman
(703-208-6689)
Status: Open- not currently enrolling
Hours of Operation
Center for Liver Diseases hours of operation:
8:30 a.m. - 5 p.m. Monday -
Friday
Questions?
Contact our office by phone
703-208-6650
or by fax at
703-208-6655
